India's Zydus Cadila seeks approval for its 3-dose COVID vaccine
The Peninsula
BENGALURU: Indian drugmaker Zydus Cadila said on Thursday it has applied for emergency use approval of its three-dose COVID-19 vaccine that showed efficacy of 66.6% in an interim study and could become the second home-grown shot if regulators consent.
Although coronavirus infections have dropped from a devastating peak in April and May that strained healthcare facilities, experts have warned of a third wave, saying widespread vaccination is one of the best pandemic defences. Zydus' vaccine "will certainly help in ramping up India's overall vaccination drive as it would be the fifth approved," Prashant Khadayate, a pharmaceutical industry analyst at GlobalData said.More Related News